Bank of New York Mellon
CSTL icon

Bank of New York Mellon’s Castle Biosciences CSTL Stock Holding History

Bank of New York Mellon’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Buy
98,018
+9,364
+11% +$209K ﹤0.01% 2858
2026
Q1 		$2.18M Buy
88,654
+1,670
+2% +$54.7K ﹤0.01% 2770
2025
Q4 		$3.38M Sell
86,984
-7,032
-7% -$227K ﹤0.01% 2542
2025
Q3 		$2.14M Buy
94,016
+4,133
+5% +$84K ﹤0.01% 2769
2025
Q2 		$1.84M Buy
89,883
+5,842
+7% +$108K ﹤0.01% 2792
2025
Q1 		$1.68M Sell
84,041
-418
-0.5% -$10.3K ﹤0.01% 2776
2024
Q4 		$2.25M Buy
84,459
+7,881
+10% +$240K ﹤0.01% 2710
2024
Q3 		$2.18M Sell
76,578
-20,110
-21% -$512K ﹤0.01% 2706
2024
Q2 		$2.1M Buy
96,688
+12,583
+15% +$280K ﹤0.01% 2766
2024
Q1 		$1.86M Sell
84,105
-9,203
-10% -$200K ﹤0.01% 2797
2023
Q4 		$2.01M Buy
93,308
+12,167
+15% +$214K ﹤0.01% 2832
2023
Q3 		$1.37M Buy
81,141
+1,058
+1% +$18.5K ﹤0.01% 3004
2023
Q2 		$1.1M Sell
80,083
-1,285
-2% -$26K ﹤0.01% 3145
2023
Q1 		$1.85M Sell
81,368
-1,614
-2% -$39.4K ﹤0.01% 2848
2022
Q4 		$1.95M Buy
82,982
+1,964
+2% +$45.5K ﹤0.01% 2862
2022
Q3 		$2.11M Buy
81,018
+9,780
+14% +$274K ﹤0.01% 2808
2022
Q2 		$1.56M Sell
71,238
-30,648
-30% -$712K ﹤0.01% 2969
2022
Q1 		$4.57M Buy
101,886
+14,658
+17% +$606K ﹤0.01% 2474
2021
Q4 		$3.74M Sell
87,228
-1,270
-1% -$66.4K ﹤0.01% 2617
2021
Q3 		$5.88M Buy
88,498
+7,143
+9% +$503K ﹤0.01% 2405
2021
Q2 		$5.97M Buy
81,355
+3,342
+4% +$221K ﹤0.01% 2398
2021
Q1 		$5.34M Sell
78,013
-7,325
-9% -$551K ﹤0.01% 2421
2020
Q4 		$5.73M Sell
85,338
-6,736
-7% -$365K ﹤0.01% 2298
2020
Q3 		$4.74M Buy
92,074
+36,300
+65% +$1.61M ﹤0.01% 2249
2020
Q2 		$2.1M Buy
55,774
+8,205
+17% +$280K ﹤0.01% 2650
2020
Q1 		$1.42M Buy
47,569
+21,383
+82% +$645K ﹤0.01% 2735
2019
Q4 		$900K Buy
+26,186
New +$640K ﹤0.01% 3299

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $9.45B AUM 27.66% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon's CSTL Position: Q2 2026 in Review

Bank of New York Mellon increased its Castle Biosciences (CSTL) stake by 11% in Q2 2026, buying an estimated $209K and bringing the position to 98,018 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2858.

Bank of New York Mellon first reported a position in CSTL in Q4 2019 and has held it in 27 quarters since. The position peaked at $5.97M in Q2 2021. 71 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Bank of New York Mellon held 98,018 shares of Castle Biosciences worth $2.34M as of Q2 2026.
  • Bank of New York Mellon bought 9,364 Castle Biosciences shares in Q2 2026, an estimated $209K.
  • Castle Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2858 holding.
  • Bank of New York Mellon first reported a position in Castle Biosciences in Q4 2019 and has held it in 27 quarters since.
  • Bank of New York Mellon's Castle Biosciences position peaked at $5.97M in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.